Skip to content

MammaPrint Value for Pre-menopausal Breast Cancer Patients

The Value of MammaPrint in Adjuvant Therapy Decision Among Pre-menopausal Breast Cancer Patients: a Survey Based on Clinical Staff

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05474391
Enrollment
200
Registered
2022-07-26
Start date
2022-07-15
Completion date
2024-07-15
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

Nearly 200 cases are to be enrolled. The information of patient age, histologic grade, tumor size, ER and PR status, Ki-67 index, surgery mode should be provided. The adjuvant therapy regime (chemotherapy: none, TC\*4, TC\*6 or EC-T; endocrine therapy: TAM, OFS+TAM, OFS+AI) will be compared before and after MammaPrint testing. About 20 clinical staffs are enrolled to participate in this survey for the clinical decision making. Each case could be chosen five times at random.

Interventions

None listed

Sponsors

Fudan University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
No minimum to 50 Years
Healthy volunteers
No

Inclusion criteria

1. pre-menopausal breast cancer patients aged less than 50 years old. 2. Pathology confirmed invasive dutal carcinoma or invasive lobular carcinoma. 3. receiving breast conserving surgery or mastectomy with/without reconstruction; sentinel lymph node biopsy or axillary lymph node dissection. 4. TNM staging: T1b-T2N0-1M0. 5. molecular subtype: ER positive/HER2 negative. 6. MammaPrint testing before initiation of adjuvant therapy.

Exclusion criteria

1. Incomplete medical history. 2. Pregnancy or lactation. 3. Contradiction of chemotherapy or ovarian function suppression.

Design outcomes

Primary

MeasureTime frameDescription
Treatment decision survey6 weeksTreatment decision change after MammaPrint testing

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026